Status:
UNKNOWN
Skeletal Events of Hormonal Treatment and Radiotherapy in Patient With Breast Cacer
Lead Sponsor:
Assiut University
Conditions:
Breast Cancer
Eligibility:
FEMALE
40-70 years
Brief Summary
study of lymphedema and skeletal events in breast cacer patient receiving adjuvant hormonal therapy and radiothearpy
Detailed Description
In the United States, it is estimated that there are more than 3.8 million living women has a history of invasive breast cancer, and 268,600 women will be newly diagnosed in 2019. Sixty-four percent o...
Eligibility Criteria
Inclusion
- Postmenopausal patients with positive diagnosis of stage 1-3 breast cancer and planned AI (anastrazole, letrozole) adjuvant treatment will be included in the study.
- Patients without known osteoporosis will included in the study, and before AI treatment began.
- Conventional RT course must be completed (50 Gy/25 fractions, 2 Gy/fraction, 5 days/week).
- Patients continue to receive adjuvant hormonal treatment (aromatase inhibitors) or adjuvant target therapy (trastuzumab) while monitoring late toxicities
Exclusion
- Male patients
- Metastatic disease at presentation
- No definitive surgery
- Carcinoma in situ or other rare tumors of the breast as phyllodes tumors.
Key Trial Info
Start Date :
December 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04792840
Start Date
December 1 2021
End Date
December 1 2021
Last Update
March 11 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.